Stock Events

Stock Events

Summit Therapeutics 

$13.16
200
+$0.73+5.87% Friday 20:00
+$0.05+0.4%Friday 23:56After hours

Statistics

Day High
13.17
Day Low
13.15
52W High
30.05
52W Low
12.07
Volume
142,837
Avg. Volume
-
Mkt Cap
10.5B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.76
-0.53
-0.31
-0.08
Expected EPS
-0.292923
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-1.08BNet Income

Analyst Ratings

21.28Average Price Target
The highest estimate is 38.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
29%
Hold
57%
Sell
14%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SMMT. It's not an investment recommendation.
NVIDIA
45
NVDA
Microsoft
35
MSFT
Amazon
29
AMZN
Alphabet
29
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is a direct competitor in the cystic fibrosis market, where Summit Therapeutics is also aiming to make significant advancements.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences competes in the antiviral space, particularly in treatments for HIV, hepatitis B, and hepatitis C, areas where Summit Therapeutics has shown interest.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie competes in the area of infectious diseases and immunology, which overlaps with Summit's research interests.
Merck
MRK
Mkt Cap335.14B
Merck & Co. is involved in developing therapies for infectious diseases, including antibiotics and antivirals, making it a competitor to Summit Therapeutics.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a broad portfolio that includes treatments for infectious diseases, directly competing with Summit Therapeutics' focus areas.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca has a diverse portfolio that includes treatments for infections, competing with Summit Therapeutics in the infectious disease space.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the area of infectious diseases, an area of focus for Summit Therapeutics.
Novartis
NVS
Mkt Cap286.78B
Novartis competes in multiple therapeutic areas, including those targeted by Summit Therapeutics, such as infectious diseases.
AMGEN
AMGN
Mkt Cap224.63B
Amgen focuses on innovative therapeutics in areas that could overlap with Summit Therapeutics' interests, including treatments for serious illnesses.
Biogen
BIIB
Mkt Cap31B
Biogen's focus on novel therapies for neurological and neurodegenerative diseases places it in competition with Summit Therapeutics' broader focus on innovative treatments.

About

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Show more...
CEO
Robert W. Duggan
Employees
265
Country
United States
ISIN
US86627T1088

Listings

MX
MX
SMMT.MX
XNAS
US
SMMT
BOATS
BOATS
SMMT.BOATS

0 Comments

Share your thoughts

FAQ

What is Summit Therapeutics stock price today?▼
The current price of SMMT is $13.16 USD — it has increased by +5.87% in the past 24 hours. Watch Summit Therapeutics stock price performance more closely on the chart.
What is Summit Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Summit Therapeutics stocks are traded under the ticker SMMT.
Is Summit Therapeutics stock price growing?▼
SMMT stock has fallen by -1.42% compared to the previous week, the month change is a -10.72% fall, over the last year Summit Therapeutics has showed a -49.77% decrease.
What is Summit Therapeutics market cap?▼
Today Summit Therapeutics has the market capitalization of 10.5B
When is the next Summit Therapeutics earnings date?▼
Summit Therapeutics is going to release the next earnings report on November 11, 2026.
What were Summit Therapeutics earnings last quarter?▼
SMMT earnings for the last quarter are -0.28 USD per share, whereas the estimation was -0.27 USD resulting in a -2.04% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Summit Therapeutics revenue for the last year?▼
Summit Therapeutics revenue for the last year amounts to 0 USD.
What is Summit Therapeutics net income for the last year?▼
SMMT net income for the last year is -1.08B USD.
How many employees does Summit Therapeutics have?▼
As of August 22, 2026, the company has 265 employees.
In which sector is Summit Therapeutics located?▼
Summit Therapeutics operates in the Health & Wellness sector.
When did Summit Therapeutics complete a stock split?▼
Summit Therapeutics has not had any recent stock splits.
Where is Summit Therapeutics headquartered?▼
Summit Therapeutics is headquartered in MIAMI, United States.